56 results on '"A. Bearz"'
Search Results
2. Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALKVariant Type and ALKWith or Without TP53Mutations
3. Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With -Positive Advanced Non-Small-Cell Lung Cancer From the Phase III CROWN Study.
4. Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2)
5. Prospective phase II study of sunitinib rechallenge in metastatic renal cell carcinoma: The “retry” study from the Italian Group of Onco-Nephrology (G.I.O.N.)
6. Chylous Ascites as a Possible Rare Side Effect of Selpercatinib in RET-Positive NSCLC
7. Endocrine toxicity in cancer patients treated with nivolumab or pembrolizumab: results of a large multicentre study
8. Sorafenib Versus Observation Following Radical Metastasectomy for Clear-cell Renal Cell Carcinoma: Results from the Phase 2 Randomized Open-label RESORT Study
9. MA18.10 Phase 2 Multicohort Study of CC-90011, a LSD1 Inhibitor, in Combination with Nivolumab in Patients with Advanced Lung Cancer
10. 21P Bevacizumab plus atezolizumab and chemotherapy in NSCLC harbouring EGFR mutation previously treated with EGFR tyrosine kinase inhibitor: The BACH-NET study
11. 60 CONTACT-01: Efficacy and safety from a phase III study of atezolizumab (atezo) + cabozantinib (cabo) vs docetaxel (doc) monotherapy in patients (pts) with metastatic NSCLC (mNSCLC) previously treated with checkpoint inhibitors and chemotherapy
12. Safety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Lung Cancer
13. Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)–Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study
14. Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.
15. Clinical presentation and outcome of non-AIDS defining cancers, in HIV-infected patients in the ART-era: the Italian Cooperative Group on AIDS and tumors activity.
16. ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC)
17. Lung cancer in HIV positive patients: the GICAT experience.
18. EP02.04-001 Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-Positive NSCLC: ALNEO Phase II Trial (GOIRC-01-2020)
19. Combination of Chemotherapy and ALK Inhibitors in ALK-Positive NSCLC
20. Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non small-cell lung cancer: the MILES-2P studies.
21. Oxaliplapin and Capecitabine (XELOX) Based Chemotherapy in the Treatment of Metastatic Colorectal Cancer: The Right Choice in Elderly Patients
22. Treatment of Elderly Patients Affected by Lung Cancer: Why to Treat, when to Treat and what we Know
23. PS01.04 International Tailored Chemotherapy Adjuvant Trial : ITACA Trial. Final Results
24. P76.03 Efficacy and Safety of Capmatinib Plus Nivolumab in Pretreated Patients with EGFRWild-Type Non–Small Cell Lung Cancer
25. Continuation of Lorlatinib in ALK-Positive NSCLC Beyond Progressive Disease
26. Sorafenib for the treatment of unresectable hepatocellular carcinoma in HIV-positive patients
27. Tomotherapy after Pleurectomy/Decortication or Biopsy for Malignant Pleural Mesothelioma Allows the Delivery of High Dose of Radiation in Patients with Intact Lung
28. Antiblastic Treatment, for Solid Tumors, during Pregnancy: A Crucial Decision
29. Oxaliplatin Based Chemotherapy and Concomitant Highly Active Antiretroviral Therapy in the Treatment of 24 Patients with Colorectal Cancer and HIV Infection
30. MUC-1 (CA 15–3 Antigen) as a Highly Reliable Predictor of Response to EGFR Inhibitors in Patients with Bronchioloalveolar Carcinoma: An Experience on 26 Patients
31. Simplified gemcitabine and platin regimen in patients with advanced or metastatic non-small cell lung cancer (NSCLC) to be proposed as neoadjuvant therapy
32. Oral Etoposide in Elderly Patients with Advanced Non Small Cell Lung Cancer: A Clinical and Pharmacological Study
33. Metastatic Angiosarcoma of the Kidney: A Case Report with Treatment Approach and Review of the Literature
34. P1.01-84 Interaction of Lorlatinib with CYP2B6, CYP2C9, UGT, and P-gp Probe Drugs in Patients with Advanced Non-Small Cell Lung Cancer
35. Lymphangioleiomyomatosis: A Case Report and Review of the Literature
36. Metastatic Angiosarcoma of the Spleen. A Case Report and Treatment Approach
37. Occult Small Cell Lung Cancer Associated with Paraneoplastic Neurologic Syndrome: Case Report
38. Expression, Purification and Functional Characterization of a Kunitz-Type Module from Chicken Type VI Collagen
39. BIPHASIC CONTROL OF NF-κB ACTIVATION INDUCED BY THE TRIGGERING OF HLA-DR ANTIGENS EXPRESSED ON B CELLS
40. Fibronectin Binding Promotes a PKC-Dependent Modulation of NF-κB in Human T Cells
41. PL02.03 Brigatinib vs Crizotinib in Patients With ALK Inhibitor-Naive Advanced ALK+ NSCLC: First Report of a Phase 3 Trial (ALTA-1L)
42. Unusual Presentation of Metastatic Hepatocellular Carcinoma in an HIV/HCV Coinfected Patient: Case Report and Review of the Literature
43. P1.01-59 Expanding Access to Large-Scale Genomic Mutational Analyses for Patients with Advanced NSCLC in Italy
44. Acquired BRAFV600E Mutation as Resistant Mechanism after Treatment with Third-Generation EGFRTyrosine Kinase Inhibitor
45. P1.01-065 Treatment Beyond Progression with Nivolumab in Patients with Advanced Non-Squamous NSCLC: Results from the Italian Expanded Access Program
46. PS02.07 Telemedicine: A New Era for the Treatment of Patients with Cancer
47. OA 05.06 Phase 2 Study of Lorlatinib in Patients with Advanced ALK+/ROS1+Non-Small-Cell Lung Cancer
48. OA 05.07 Efficacy and Updated Safety of Ceritinib (450 Mg or 600 Mg) with Low-Fat Meal vs 750 Mg Fasted in ALK+ Metastatic NSCLC
49. MA 01.07 Lanreotide Maintenance in SCLC Expressing Somatostatine Receptors: Efficacy Results of Multicenter Randomized G04.2011 trial
50. OA 02.01 Randomized Phase II Study of Anetumab Ravtansine or Vinorelbine in Patients with Metastatic Pleural Mesothelioma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.